Figure 1.
The percentage of patients that developed grade >3 cardiotoxicity in the presence or absence of baseline cardiac comorbidities in each renal function group.
The percentage of patients that developed grade >3 cardiotoxicity in the presence or absence of baseline cardiac comorbidities in each renal function group.